Sidiropoulos, P <br/><br/>
Low dose of infliximab is inadequate in most patients with spondylarthropathies.  [electronic resource] 

 -  Clinical and experimental rheumatology   
 - 513-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0392-856X 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--economics<br/>Antirheumatic Agents--economics<br/>Arthritis, Psoriatic--drug therapy<br/>Cohort Studies<br/>Dose-Response Relationship, Drug<br/>Female<br/>Health Status<br/>Humans<br/>Infliximab<br/>Male<br/>Severity of Illness Index<br/>Spondylitis, Ankylosing--drug therapy<br/>Treatment Outcome